Brief: Eyegate Pharma Announces First Patient Dosed For Pp-001 In A Phase 2 Proof-Of-Concept Ocular Surface Inflammation Study
14/06/2021 12:05
June 14 (Reuters) - EyeGate Pharmaceuticals Inc EYEG.O :
* EYEGATE PHARMA ANNOUNCES FIRST PATIENT DOSED FOR PP-001 IN
A
PHASE 2 PROOF-OF-CONCEPT OCULAR SURFACE INFLAMMATION STUDY
* EYEGATE PHARMACEUTICALS INC - TOPLINE DATA EXPECTED IN Q4
2021
FOR PP-001
Source text for Eikon: ID:nGNXbql70c
Further company coverage: EYEG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiora Pharmaceuticals
See all newsKiora Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kiora Pharmaceuticals, Inc. expected to post a loss of 62 cents a share - Earnings Preview
Brief: Kiora Pharmaceuticals Inc - Enters Securities Purchase Agreement On April 3, 2026 - SEC Filing
Kiora Pharmaceuticals posts 2025 net loss as expenses rise
Brief: Kiora Pharmaceuticals Files For Mixed Shelf Offering Of Up To $100 Million- SEC Filing